Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Aim of this study will evaluate the Efficacy and Safety of Anti-PD-1 monoclonal antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma Patients.

Trial Details

NCT ID
NCT05182957
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Anti-PD-1 monoclonal antibody
  • Lenalidomide
  • Azacitidine
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Pathological immunohistochemistry or flow cytometry confirmed that R/R PTCL with measurable (diameter greater than 1.5cm) lesions meets any of the …
  • Age ≥ 18 years.
  • The main organ functions need to meet the following conditions:Hemogram needs to meet HB ≥70\*1012/L,PLT≥50\*109/L,NE≥1\*109/L;LVEF≥50%;CR≤132umol/…
  • Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study until th…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →